NSEAction(s) initiated or orders passed24 Oct 2026 · 24 Oct 2026, 12:17 pm

Action(s) initiated or orders passed

Sahajanand Medical Technologies Limited · SMT

✦ AI SummaryRegulatory

Sahajanand Medical Technologies Limited has received a summons under Section 70 of the Central Goods and Services Tax Act, 2017, for verification of books of accounts. The company is cooperating with the authorities and does not expect any material financial impact.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk8/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Sahajanand Medical Technologies Limited has informed the Exchange about summons received under section 70 of Central Goods and Service tax Act.

Attachments (1)

📄

SAHAJANAND_24102026121647_Disclosure_Under_Reg_30_Summons_under_GST_ACT.pdf

pdf

Download →
View document text
Ref: 05/SE/LC/2026-27 Date: October 24, 2026 To, To, National Stock Exchange of India Limited BSE Limited (“BSE”) (“NSE”) Listing Department Listing Department Corporate Relationship Department Exchange Plaza, C-1 Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Complex Bandra (East), Mumbai – 400051 Dalal Street, Fort, Mumbai - 400 001 NSE Scrip Symbol: SMT BSE Scrip Code: 545001 ISIN: INE356Y01018 ISIN: INE356Y01018 Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Ref. No: DIN 202610DWW0000018FC61 dated 16th October 2026 (received on 23rd October 2026) issued to GSTIN 27AAFCS7694L1ZI Dear Sir/Madam, Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform that the Company has received a Summons dated October 16,2026 (received on 23rd October 2026) issued under Section 70 of the Central Goods and Services Tax Act, 2017 by the Superintendent/ Appraiser/ Senior Intelligence Officer of DGGI, Mumbai Zonal Unit, Mumbai. The Summons has been issued to our GSTIN 27AAFCS7694L1ZI in connection with an initiation of inquiry under the Central Goods and Services Tax Act, 2017. At this stage, the Company is fully cooperating with the authorities and will provide all necessary information as required. This Summons does not have any material financial impact on the Company. The Company will keep the Stock Exchange(s) informed of further significant developments, if any. Details required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, as amended from time to time, are enclosed as Annexure A to this disclosure. We request you to take the afore-mentioned information on record and oblige. This is for your information and records. Thanking you, For Sahajanand Medical Technologies Limited Bhargav Dhirajlal Kotadia Managing Director & Chief Executive Officer DIN: 06575042 Annexure A Sl. Particulars Information Remarks 1 Name of the Authority Superintendent/ Appraiser/ Senior Intelligence Officer of DGGI Branch, Zonal Unit Mumbai, NTC House, 1st floor, Ballard Estate, Fort, Mumbai - 400001 2 Nature and details of the action initiated Summons issued under Section 70 of the or order passed Central Goods and Services Tax Act, 2017, for verification of books of accounts. 3 Date of receipt of notice, direction or Summons dated 16 October 2026 received on order, including any ad-interim or October 23, 2026 interim orders, or any other communication from the authority 4 Details of the The Summons does not specify violations. It violation(s)/contravention(s) committed states to give evidence in relation to GST or alleged to be committed compliance for re-imbursements made to foreign subsidiaries for clinical trials 5 Impact on financial, operation or other No material financial, operational, or business activities of the listed entity, quantifiable impact at this stage. The Company is fully in monetary terms to the extent possible. cooperating with the authorities and will provide necessary information